Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings

Abbott Laboratories (NYSE:ABT) will release its third quarter earnings report before the opening bell on Wednesday, Oct. 21.

Analysts expect the Abbott Park, Illinois-based company to report quarterly earnings of $1.41 per share, up from $1.30 per share in the year-ago period. The consensus estimate for ABT’s quarterly revenue is $12.99 billion. It reported $11.37 billion last year, according to Benzinga Pro.

On Oct. 5, Abbott received FDA approval for CardioMEMS HF System updates that add new patient-facing features through the CardioGuide HF App.

Shares of Abbott rose 0.2% to close at $104.89 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

• TD Cowen analyst Joshua Jennings maintained a Buy rating with a price target of $135 on Oct. 16, 2026. This analyst has an accuracy rate of 57%.
• Barclays analyst Matt Miksic initiated coverage on the stock with an Overweight rating with a price target of $120 on Oct. 7, 2026. This analyst has an accuracy rate of 64%.
• Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $112 to $125 on Aug. 14, 2026. This analyst has an accuracy rate of 70%.
• Wolfe Research analyst Mike Polark upgraded the stock from Peer Perform to Outperform with a price target of $130 on Aug. 13, 2026. This analyst has an accuracy rate of 51%.
• Piper Sandler analyst Adam Maeder maintained an Overweight rating and increased the price target from $115 to $118 on July 17, 2026. This analyst has an accuracy rate of 56%.

Considering buying ABT stock? Here’s what analysts think:

Photo via Shutterstock